A5083357923- Colorectal Cancer Treatments and Studies
- Economic and Financial Impacts of Cancer
- Gastric Cancer Management and Outcomes
- Health Systems, Economic Evaluations, Quality of Life
- Cancer Cells and Metastasis
- Cell Adhesion Molecules Research
- Lung Cancer Treatments and Mutations
- S100 Proteins and Annexins
- Chemotherapy-induced cardiotoxicity and mitigation
- Anorectal Disease Treatments and Outcomes
- Pancreatic and Hepatic Oncology Research
- Thyroid Cancer Diagnosis and Treatment
- Circular RNAs in diseases
- Fibroblast Growth Factor Research
- Cancer Genomics and Diagnostics
- Lung Cancer Diagnosis and Treatment
- Effects and risks of endocrine disrupting chemicals
- Protease and Inhibitor Mechanisms
- Proteoglycans and glycosaminoglycans research
- Pelvic floor disorders treatments
- Estrogen and related hormone effects
- Glycosylation and Glycoproteins Research
- Cardiac Ischemia and Reperfusion
- Cancer-related molecular mechanisms research
- Cancer, Hypoxia, and Metabolism
Tianjin University of Traditional Chinese Medicine
2023
Lilly (China)
2018-2021
Shanghai Medical Information Center
2021
China National Center for Food Safety Risk Assessment
2016
Peking University
2011-2016
German Cancer Research Center
2014-2016
Heidelberg University
2014-2016
Metastasis is the principal cause of high morbidity and mortality among breast cancer (BC) patients. Identification markers that can be routinely monitored to predict onset metastasis in BC patients prognosis metastatic (MBC) would increase their median survival. In this study, plasma miRNAs 40 MBC were profiled by TaqMan low density arrays with prognostic capacity identified. The candidates validated initially samples 237 subsequently 335 from an independent study cohort Sixteen established...
Conventional tumor markers have limited value for prognostication and treatment monitoring in metastatic breast cancer (MBC) patients novel circulating therefore need to be explored. Hyaluronic acid (HA) is a major macropolysaccharide the extracellular matrix reported associated with progression. In our study, we investigated plasma HA level respect progression free survival (PFS) overall (OS), as well MBC patients. The prognostic of was discovery cohort 212 2.5-year follow-up validated an...
Abstract Background Colorectal cancer (CRC) is the third most prevalent in China but few large-scale studies were conducted to understand CRC patients. The current study aimed gain a real-world perspectives of patients China. Methods Using electronic medical records sampled between 2011 and 2016 from 12 hospitals China, retrospective cohort was describe demographics disease prognosis patients, examine treatment sequences among metastatic (mCRC) Descriptive, comparative survival analyses...
Objectives: To describe direct medical costs associated with each line of treatment among metastatic colorectal cancer (mCRC) patients in China.Methods: Electronic records between 2011 and 2016 were extracted from 12 tertiary hospitals China for adult who initiated third-line at least nine months before the end data collection. Direct included wards, diagnostic tests, surgical procedures, special materials, drugs others. Costs assessed by treatment, drug further breakdown receiving...
The aim of this study is to assess the cost-effectiveness fruquintinib compared regorafenib as third-line treatment for patients with metastatic colorectal cancer (mCRC) in China.A three-state Markov model monthly cycle was constructed estimate lifetime incremental ratio (ICER) versus mCRC from Chinese health care perspective. Survival analysis applied calculate transition probabilities using data clinical trials FRESCO and CONCUR, which were also sources accessing adverse events. Background...
Aim: To assess whether the survival benefit of fruquintinib is quality-adjusted. Materials & methods: Data 416 metastatic colorectal cancer patients from Phase III FRESCO trial were used. The Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST) analysis assessed quality-adjusted versus placebo, accounting for freedom symptomatic disease and severe side effects treatment. Results: Fruquintinib significantly improved patients' Q-TWiST (difference: 2.23 [1.41, 3.04] months) placebo....
Abstract Background: Colorectal cancer (CRC) is the third most prevalent in China but few large-scale studies were conducted to understand CRC patients. The current study aimed gain a real-world perspectives of patients China. Methods: Using electronic medical records sampled between 2011 and 2016 from 12 hospitals China, retrospective cohort was describe demographics disease prognosis patients, examine treatment sequences among metastatic (mCRC) Descriptive, comparative survival analyses...
3544 Background: The FRESCO Study is a randomized, double-blind, phase III trial comparing fruquintinib + best supportive care (BSC), to placebo BSC in the treatment of metastatic colorectal cancer (mCRC). This ad-hoc analysis aims compare quality-adjusted survival between two arms using time without symptoms or toxicity (Q-TWiST) methodology, and investigate Q-TWiST benefit among sub-groups. Methods: for each patient was divided into 3 portions: TOX (time with ≥ grade before progression),...
37 Background: Metastasis is the main course of death in breast cancer (BC) patients. Reliable prognostic markers are very much appreciated to evaluate possible outcome Circulating tumor cells (CTC) a circulating marker metastatic Despite big technical challenges CTC detection, reliability enumeration for prognosis BC still on debate. Some studies have proved that plasma level X, major component extracellular matrix, was increased patients with cancer. However, association between X and...
Fecal incontinence is a refractory disease in colorectal surgery. The main clinical manifestation that patients cannot control the discharge of gas, solid or liquid feces rectum autonomously. It easy to bring shame and seriously affect their physical mental health. Reducing frequency fecal incontinence, restoring anal sphincter function, improving patient quality life are important goals for treating incontinence. With development medical technology improvement treatment plans with usually...
765 Background: In a randomized phase II trial of mCRC patients who have failed at least 2 lines standard therapy, fruquintinib has demonstrated superior progression free survival (PFS) and overall (OS) benefits over placebo. We further assessed the between-treatment difference quality life (QoL) using Q-TWiST analysis, to elucidate trade-off between adverse events treatment benefits. Methods: Mean PFS OS were estimated Kaplan-Meier method. in analysis was partitioned into 3 health states:...
Abstract Background: Colorectal cancer (CRC) is the third most prevalent in China but few large-scale studies were conducted to understand CRC patients. The current study aimed gain a real-world perspectives of patients China. Methods: Using electronic medical records sampled between 2011 and 2016 from 12 hospitals China, retrospective cohort was describe demographics disease prognosis patients, examine treatment sequences among metastatic (mCRC) Descriptive, comparative survival analyses...
Abstract Background: Colorectal cancer (CRC) is the third most prevalent in China but few large-scale studies were conducted to understand CRC patients. The current study aimed gain a real-world perspectives of patients China. Methods: Using electronic medical records sampled between 2011 and 2016 from 12 hospitals China, retrospective cohort was describe demographics disease prognosis patients, examine treatment sequences among metastatic (mCRC) Descriptive, comparative survival analyses...